Joshua Schafer
Director/Board Member at PHARNEXT SCA
Net worth: 16 501 $ as of 29/04/2024
Joshua Schafer active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PHARNEXT SCA | Director/Board Member | 27/12/2022 | - |
| Chief Executive Officer | 26/11/2022 | 27/12/2022 | |
| Chairman | 29/03/2022 | 27/12/2022 | |
| Independent Dir/Board Member | 15/06/2022 | 26/11/2022 | |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 31/12/2018 | - |
| Independent Dir/Board Member | 31/12/2018 | - | |
| ZEVRA THERAPEUTICS, INC. | Corporate Officer/Principal | 08/01/2023 | - |
| ACER THERAPEUTICS INC. | Director/Board Member | 16/11/2023 | - |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Director/Board Member | - | - |
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Consultant / Advisor | - | - |
Career history of Joshua Schafer
Former positions of Joshua Schafer
| Companies | Position | Start | End |
|---|---|---|---|
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Staines Upon Thames, UK and was founded in 2015. | Corporate Officer/Principal | 31/12/2017 | 01/11/2022 |
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | - | - |
Training of Joshua Schafer
| Northwestern University | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Statistics
International
| United States | 7 |
| France | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 4 |
| Corporate Officer/Principal | 3 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| PHARNEXT SCA | Health Technology |
| ASTELLAS PHARMA INC. | Health Technology |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Staines Upon Thames, UK and was founded in 2015. | Health Technology |
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
- Stock Market
- Insiders
- Joshua Schafer
- Experience
